1-(bromomethyl)-3-tert-butyl-5-iodobenzene | 711022-63-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(bromomethyl)-3-tert-butyl-5-iodobenzene
• 英文别名: 1-(Bromomethyl)-3-(tert-butyl)-5-iodobenzene
• CAS: 711022-63-8
• 化学式: C₁₁H₁₄BrI
• 分子量: 353.041
• InChiKey: IKMNHLDEDSQSII-UHFFFAOYSA-N

物化性质

• 沸点：
  314.1±30.0 °C(Predicted)
• 密度：
  1.699±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  1-(bromomethyl)-3-tert-butyl-5-iodobenzene 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 正丁基锂 、 potassium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 为溶剂， 反应 72.17h， 生成 tetraisopropyl 2-(3-ethnyl-5-tert-butylphenyl)ethan-1,1-bisphosphonate
  参考文献：
  名称：

  Bisphosphonate esters interact with HMG-CoA reductase membrane domain to induce its degradation

  摘要：

  HMG-CoA reductase (HMGCR) is a rate-limiting enzyme in the cholesterol biosynthetic pathway, and its catalytic domain is the well-known target of cholesterol-lowering drugs, statins. HMGCR is subject to layers of negative feedback loops; excess cholesterol inhibits transcription of the gene, and lanosterols and oxysterols accelerate degradation of HMGCR. A class of synthetic small molecules, bisphosphonate esters exemplified by SR12813, has been known to induce accelerated degradation of HMGCR and reduce the serum cholesterol level. Although genetic and biochemical studies revealed that the accelerated degradation requires the membrane domain of HMGCR and Insig, an oxysterol sensor on the endoplasmic reticulum membrane, the direct target of the bisphosphonate esters remains unclear. In this study, we developed a potent photoaffinity probe of the bisphosphonate esters through preliminary structure-activity relationship study and demonstrated binding of the bisphosphonate esters to the HMGCR membrane domain. These results provide an important clue to understand the elusive mechanism of the SR12813-mediated HMGCR degradation and serve as a basis to develop more potent HMGCR degraders that target the non-catalytic, membrane domain of the enzyme.

  DOI：

  10.1016/j.bmc.2020.115576
• 作为产物：
  描述：

  间碘甲苯 在 aluminum (III) chloride 、 过氧化苯甲酰 作用下， 以 四氯化碳 为溶剂， 反应 1.0h， 生成 1-(bromomethyl)-3-tert-butyl-5-iodobenzene
  参考文献：
  名称：

  [EN] MONOACYLGLYCEROL LIPASE MODULATORS
  [FR] MODULATEURS DE LA MONOACYLGLYCÉROL LIPASE

  摘要：

  3.1.0和4.1.0 Azabicycle化合物的化学式（I），含有它们的药物组合物，制备它们的方法，以及使用它们的方法，包括用于治疗与MGL调节相关的疾病状态、疾病和症状的方法，例如与疼痛、精神障碍、神经系统疾病（包括但不限于重度抑郁症、治疗抵抗性抑郁症、焦虑性抑郁症、躁郁症）、癌症和眼部疾病相关的方法。其中X、Y、R1、R2a和R2b在此处定义。

  公开号：

  WO2021160602A1

文献信息

• [EN] SUBSTITUTED PYRAZOLE ANALOGUES AS RAR ANTAGONISTS<br/>[FR] ANALOGUES DE PYRAZOLE SUBSTITUÉS EN TANT QU'ANTAGONISTES DE RAR
  申请人：LILLY CO ELI

  公开号：WO2013066640A1

  公开（公告）日：2013-05-10

  The present invention provides compounds of Formula I or a pharmaceutical salt thereof; methods of treating osteoarthritis and the pain associated with osteoarthritis using the compounds; and processes for preparing the compounds.

  本发明提供了式I化合物或其药物盐；使用该化合物治疗骨关节炎及其相关疼痛的方法；以及制备该化合物的方法。
• Benzoxazin-3-ones and derivatives thereof as therapeutic agents
  申请人：——

  公开号：US20040121996A1

  公开（公告）日：2004-06-24

  The present invention provides compounds of Formula I 1 wherein W, Q, E, D, R 6 , R 7 , R 8 , Y, K, R 9 , R 10 , R 12 , G, and the double bond denoted “*” have any of the values defined therefore in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cardiovascular diseases, and cancers. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.

  本发明提供了I式化合物，其中W，Q，E，D，R6，R7，R8，Y，K，R9，R10，R12，G和表示为“*”的双键具有规范中定义的任何值，并且其药学上可接受的盐，可用作治疗疾病和病症的药物，包括炎症性疾病，心血管疾病和癌症。还提供了包含一种或多种I式化合物的制药组合物。
• US20140275049A1
  申请人：——

  公开号：——

  公开（公告）日：——
• BENZOXAZIN-3-ONES AND DERIVATIVES THEREOF AS INHIBITORS OF PI3K
  申请人：Warner-Lambert Company LLC

  公开号：EP1569653A1

  公开（公告）日：2005-09-07
• MONOACYLGLYCEROL LIPASE MODULATORS
  申请人：Janssen Pharmaceutica NV

  公开号：US20210253565A1

  公开（公告）日：2021-08-19

  3.1.0 and 4.1.0 Azabicycle compounds of Formula (I), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. wherein X, Y, R 1 , R 2a , and R 2b are defined herein.